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Abstract: Zebrafish (Danio rerio) is a bona fide vertebrate model system for understanding human diseases. It allows the 
transparent visualization of the effects of ionizing radiation and the convenient testing of potential radioprotectors with 
morpholino-modified oligonucleotides (MO) knockdown. Furthermore, various reverse and forward genetic methods are 
feasible to decipher novel genetic modifiers of radioprotection. Examined in the review are the radioprotective effects of 
the proposed radiomodifiers Nanoparticle DF-1 (C-Sixty, Inc., Houston, TX) and Amifostine (WR-2721, Ethyol), the 
DNA repair proteins Ku80 and ATM, as well as the transplanted hematopoietic stem cells in irradiated zebrafish. The 
presence of any of these sufficiently rescued the radiation-induced damages in zebrafish, while its absence resulted in 
mutagenic phenotypes as well as an elevation of time- and dose-dependent radiation-induced apoptosis. Radiosensitizers 
Flavopiridol and AG1478, both of which block progression into the radioresistant S phase of the cell cycle, have also been 
examined in zebrafish. Zebrafish has indeed become a favorite model system to test for radiation modifiers that can poten-
tially be used for radiotherapeutic purposes in humans.  
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I. ZEBRAFISH AS AN IDEAL MODEL SYSTEM 
 Zebrafish  (Danio rerio) has been envisioned as a popular 
vertebrate model system for studying radioprotection. The 
extensive forward genetic screens in the 1990s initiated the 
study of genes affecting zebrafish embryonic development 
[1, 2], and since then a large number of zebrafish mutants 
exhibiting rare human diseases have been obtained. Recent 
studies on zebrafish as a model system have provided impor-
tant insight into various human diseases of oncogenic, neu-
rodegenerative, hematopoietic, and cardiovascular origin [3-
6]. Despite the evolutionary divergence nearly 450 million 
years ago, the human and zebrafish genome exhibit consid-
erable homology with the conservation of key genes in-
volved in development, signal transduction, cell cycle pro-
gression and proliferation, and cell differentiation [7-11]. 
The effects of ionizing radiation on the two organisms and 
the extent of phenotypic rescue by radioprotective sub-
stances are also similar.  
  Most importantly, zebrafish offers far more practical 
benefits as a laboratory model system than any other organ-
ism. At low cost and with ease of care, large numbers of ze-
brafish can be maintained in a small space wherein frequent 
paired matings produce hundreds of embryos at a time. Its 
optical transparency of embryos allows the visualization of 
major organ systems during the rapid 3 months of embryonic 
development. Within 48 hours postfertilization (hpf), major 
organ systems such as the eyes, brain, heart, liver, muscles, 
bones, and the GI tract are evident. External embryogenesis 
also allows experimental manipulations to be conveniently 
carried out without parental sacrifice. Genetic manipulations  
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in zebrafish, moreover, are relatively simple since the mi-
croinjection of morpholino-modified oligonucleotides com-
plementary to the target gene or mRNA expressed from the 
target can be used to generate genetic knockouts [12, 13]. 
The morpholinos degrade after 4 days, however, making it 
difficult to assess the long-term effects of gene inhibition. 
Regardless, the 4 day time frame is adequate enough to 
evaluate the immediate effects of gene inactivation in zebraf-
ish embryos and adults.  
  The aforementioned benefits of using zebrafish as a ver-
tebrate model system are only beginning to be appreciated, 
however, and the studies of radiation effects on zebrafish lag 
behind. Nonetheless, gamma-rays were shown to be an effi-
cient mutagen in zebrafish [14, 15] that can generate a spe-
cific locus mutation rate of ~1:100. Subsequent gamma-ray 
mutagenesis studies produced interesting mutations affecting 
zebrafish embryogenesis [16-18]. A reverse genetic approach 
in the 1990s was then adopted to identify the affected genes 
from the isolated mutant phenotypes. Despite the significant 
efforts to establish a genetic map of the zebrafish genome 
[19, 20], far more needs to be done before the molecular 
mechanisms behind radiation-induced mutations are revealed 
and available for radiotherapeutic manipulations.  
II. RADIOPROTECTORS: DF-1 AND AMIFOSTINE 
  The success of cancer radiotherapy depends on the selec-
tive sparing of normal tissues. For decades, the enhancement 
of therapeutic index has thus been a central topic. As treat-
ment strategies that can minimize radiation-induced toxicity, 
recent advances in radiation delivery technology such as 
Intensity-Modulated Radiotherapy (IMRT) [21, 22] and frac-
tionation strategies [23] have been examined. More promis-
ing is the discovery of a large number of radioprotective sub-
stances [24], some of which selectively enter normal cells  
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Amifostine and DF-1 have been shown to reverse the effects 
of total body irradiation (TBI) in animal models including 
zebrafish. Revealing their precise mechanism of radioprotec-
tion therefore has significant clinical implications. 
A. DF-1 
  Nanoparticle DF-1 (C-Sixty, Inc., Houston, TX) is a wa-
ter-soluble fullerene with antioxidant properties [25, 26]. 
Fullerenes refer to a family of molecules containing 20, 40, 
60, 70, or 84 carbon atoms, and DF-1 is a C60 derivative 
(dendrofullerene) structurally modified to enhance water 
solubility and reduce toxicity. The unaltered Buckminster 
fullerene C60  has been demonstrated to exert toxic effects 
both in vitro and in vivo, such as in the aquatic largemouth 
bass [27]. Since fullerenes act as scavengers of reactive oxy-
gen species (ROS) including hydrogen peroxide, hydroxyl 
radicals, and superoxide [28], it is thought that the antioxi-
dant properties of DF-1 enables and accounts for its radio-
protective role. If not blocked, the generated ROS can induce 
DNA damage and carcinogenesis [29, 30].  
i. Radioprotection in Zebrafish 
  A recent study by Daroczi and colleagues shows that DF-
1 alleviates toxicity associated with irradiation of zebrafish 
embryos in vivo without exerting adverse effects on normal 
zebrafish morphology or viability throughout the concentra-
tion range tested (1-1,000 micromol/L). The group exposed 
zebrafish embryos to DF-1 at 24 hpf and monitored radiation 
effects up to day 6. The developmental stage of 24 hpf was 
preferably chosen since organ formation during this time is 
thought to be particularly sensitive to external radiation. Ion-
izing radiation ranging from 10 to 40 Gy caused time- and 
dose-dependent perturbations and lethality. Adverse radia-
tion effects on the surviving zebrafish included defective 
midline development resulting in dorsal curvature of the 
body axis (“curly-up”) or cup [31], neurotoxicity, and im-
paired excretory function. The administration of DF-1 was 
able to reverse all of these side effects, the most noticeable 
by appearance being the reduced incidence of the cup pheno-
type. Edema due to impaired renal function is a well docu-
mented radiation side effect in mammals [32], and neurotox-
icity is also a well known consequence of the central nervous 
system radiotherapy. The ability of DF-1 to diminish neuro-
toxicity was associated with the reduction of radiation-
induced nerve cell damage and ROS production. The amount 
of stained neuromasts significantly decreased upon 80 Gy 
exposure at 50 days postfertilization (dpf), but such effect 
was inhibited by DF-1 pretreatment. The marked reduction 
of radiation-induced ROS was similarly measured using a 
fluorescent dye. The efficiency of DF-1 as a radioprotector 
depended upon its dose and time of application, however. 
The maximal radioprotective activity was exhibited at the 
concentration of 100μmol/L and when given within 3 hours 
before or up to 15 minutes after radiation (20Gy) exposure. 
When exposed to DF-1 30 minutes after ionizing radiation, 
zebrafish embryos were not protected from the harmful ef-
fects of radiation. Having ascertained the radioprotective 
effects of DF-1 in zebrafish, the next step would be to exam-
ine the molecular workings behind its dose- and time-
dependent action. 
B. Amifostine (WR-2721, Ethyol) 
i. Pharmacology 
  Nearly 50 years have passed since the discovery of thiol-
containing amino acid cysteine as having remarkable radio-
protective potentials [33]. The extensive testing of more than 
4,000 sulfhydryl-containing substances then followed at the 
Walter Reed Army Institute of Research, ultimately yielding 
only one radioprotector amifostine as having acceptable tox-
icity [34]. Amifostine differs from DF-1 in that it possesses 
the ability to selectively protect normal tissues not only from 
irradiation but also from chemotherapy [35, 36]. Several 
studies have demonstrated its selective sparing of normal 
tissue when administered with several antineoplastic drugs, 
including cisplatin, carboplatin, carmustine, cyclophos-
phamide, doxorubicin, fluorouracil, melphalan, mitomycin, 
mechlorethamine, and paclitaxel [37-44]. In 1996, the Food 
and Drug Administration (FDA) approved the use of ami-
fostine as a cytoprotective agent in cisplatin-based chemo-
therapy against ovarian cancer. Recently, amifostine has 
been approved for use in head and neck cancer to prevent 
radiation-induced xerostomia [45, 46]. It may also help ame-
liorate mucosal reactions that function as a limiting factor in 
accelerated fractionation or chemoradiation treatments. 
Many clinical trials are thus being carried out to test its po-
tential use as a clinical radioprotector in broader terms [21, 
47-51]. Clinical application of amifostine, however, is cur-
rently limited by its harmful side effects including hypoten-
sion, pruritus, and flushing [52]. Moreover, not one study so 
far has had the sufficient statistical power to conclude that 
amifostine does not reduce antitumor efficacy.  
  Much attention has been given to the pharmacologic 
properties of amifostine due to its unique ability of confer-
ring radioprotection only to normal cells. With a half-life of 
1 to 3 minutes in plasma, amifostine is rapidly dephosphoryl-
ized to its active metabolite WR-1065 after intravenous ad-
ministration [53]. Dephosphorylation is believed to be 
caused by spontaneous nonenzymatic hydrolysis or by an 
enzymatic catalysis involving alkaline phosphatase under the 
optimal pH of 8 or 9 [54]. Radiolabeled amifostine has re-
vealed that its active metabolite WR-1065 accumulates in 
most normal tissues shortly upon injection into mice [54, 
55], but preferentially more in certain tissues. Whereas ex-
tensive uptake was seen in salivary glands, kidneys, and in-
testinal mucosa, a markedly lower uptake was exhibited in 
tumor tissues [53-55]. The elimination rate of WR-1065 
similarly varies considerably between tissues. The drug con-
centration in lung and skin decline rapidly during the first 30 
minutes but remain elevated in salivary glands for up to 3 
hours [55].  
  Several explanations have been offered to explain for 
such selectivity of tissues. The hydrophilic characteristics of 
amifostine make it difficult to cross cell membranes [36] or 
the blood-brain barrier [56, 57]. Despite the blood-brain bar-
rier, amifostine has been shown neuroprotective effects when 
co-administered with chemotherapeutic agents [58, 59]. In 
contrast to normal tissues that can uptake amifostine by ac-
tive transport, tumor cells absorb the agent via passive diffu-
sion [54]. Given the unfavorable charge difference between 
amifostine and tumor cell membrane, passive diffusion may  
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account for the significantly less uptake of the drug by tumor 
cells. Additionally, the differences between normal and tu-
mor tissue perfusion, pH, hypoxia, and alkaline phosphatase 
activity have been regarded as potential selectivity determin-
ing factors [60-62].  
  Both oxygen-dependent and oxygen-independent path-
ways may be involved in the generation of radioprotection 
by amifostine. Substantial evidence suggests that oxygen 
concentration differences, rather than the tissue-dependent 
amifostine concentrations, may be of greater importance in 
conferring radioprotection [60, 62, 63]. In fact, WR-1065 
and, to a lesser extent, its intracellular disulfide metabolic 
product WR-33278 act as free radical scavengers in protect-
ing cellular damage [64, 65]. Independently of oxygen, it 
was shown that thiols may aid in chemical repair via hydro-
gen donation [66] and in the induction of DNA packaging 
which decreases the accessibility of radiolytic attack sites 
[64]. Furthermore, WR-33278 exhibits structural similarities 
to naturally occurring polyamines [67] known to influence 
DNA synthesis, DNA repair, gene expression, and cell cycle 
progression [67-69]. These characteristics of WR-33278 may 
explain the antimutagenic effect of amifostine even when 
administered up to 3 hours after irradiation [70]. 
ii. Radioprotection in Zebrafish 
 Geiger  et al. demonstrated in a zebrafish model that ami-
fostine can ameliorate the toxic effects ionizing radiation 
[71, 72]. Embryos were exposed to varying degrees of 
gamma-radiation (5, 10, or 20 Gy) at sequential times post 
fertilization for viability and morphology assessments. Sur-
viving embryos were markedly malformed, with shortened 
and curved bodies, defects in the head and eyes, pericardial 
edema, along with the inhibition of yolk sac resorption [72, 
73]. Such radiation-induced malformations show similarity 
to that noted in mammals. Inadvertent or therapeutic expo-
sure to radiation in humans reportedly results in cataract 
formation, retinal degeneration/atrophy, blindness, and mi-
crocephaly [74-80]. Of the many IR complications seen in 
the zebrafish study by Geiger and colleagues, the brain and 
eyes were markedly affected. The volume of the tectum of 
the brain decreased dramatically and the organization of reti-
nal cellular layers was noticeably perturbed.  
  Not only was amifostine able to rescue the above pheno-
types, it also blocked the caspase activation in the brain   
and eyes as detected through terminal deoxyribonucleotidyl 
transferase-mediated dUTP nick end labeling (TUNEL) as-
says. Previously shown with the TUNEL assay was the pres-
ence of apoptosis in the irradiated zebrafish hindbrain and 
the peripheral nervous system [73]. The level of apoptosis 
upon irradiation was seen through an in vitro assay detecting 
the bioluminescent imaging of caspase activity in zebrafish 
embryos. Treatment with amifostine or pancaspase inhibitor 
Z-VAD-fmk displayed a significant increase in light emis-
sion than without the treatment, signifying the presence of 
more apoptosis-resistant embryos. Of the two caspase levels 
measured, substantially more caspase 9 activation was noted 
than that of caspase 8. Interestingly, the amount of caspase 
activation at 20 Gy was not twice that of 10 Gy suggesting 
that the extent of caspase activation may not be proportional 
to the radiation dose beyond an “optimal” radiation dose 
range. To better account for the conditions under which ami-
fostine enhanced the survival rate of irradiated zebrafish em-
bryos, the group coined and defined the radioprotection ratio 
as the proportion of surviving embryos under amifostine and 
a given dose of IR treatment divided by the proportion sur-
viving the same dose of IR in the absence of amifostine. 
Embryos were thus irradiated at 2, 4, 6, 8, or 24 hpf with 5, 
10, 20 Gy and assessed every 24 hours until 144 hpf. The 
result showed that the radioprotective effects of amifostine 
depend on the age of the embryo at the time of irradiation as 
well as the dose delivered. At all doses of radiation, the 
greatest radioprotection was conferred to the younger em-
bryos irradiated up to 8 hpf.  
  Previous reports point out the correlation between em-
bryonic age and radiosensitivity, a link that may provide an 
explanation to the variant radioprotection ratios based on the 
different times of amifostine and radiation administration. 
Many studies have also found increased radiosensitivity at 
earlier points of embryonic development. Gastrulation dur-
ing zebrafish embryonic development refers to the first de-
finable point at which organ development begins and gener-
ally occurs around 5 to 7 hpf [81]. It has been shown that the 
susceptibility of the embryos to the lethal effects of radiation 
diminishes after this point, bolstering the hypothesis that the 
times at or before gastrulation are particularly radiosensitive 
[15]. Exposure to IR during the sensitive ‘critical periods’ of 
organ-specific formation or morphogenesis has been demon-
strated to cause tissue-specific malformation [82, 83]. Early 
reports with zebrafish mutagenesis similarly found enhanced 
radiosensitivity before the midblastula transition (MBT) as 
compared with later developmental stages [15]. However, 
Walker and colleagues did not score the effects of different 
radiation doses nor categorize the severity of mutations. To 
account for the time-dependency of radiosensitivity during 
embryonic development, McAleer et al. hypothesized that 
the noted nonspecific manifestations of irradiation mutage-
nesis during early embryonic development [2] may be due to 
the absence of repair proteins before MBT, before which 
maternal proteins present in yolk govern all processes. In 
other words, the reversal of radiation-incurred DNA damage 
seems to require the transcription of necessary repair genes 
by the embryo proper after MBT [84].  
  Evidences suggest that self-elimination, rather than dam-
age reparation, may be the favored adaptive response to ra-
diation during IR-sensitive periods such as the organogenic 
stage. Little or no radiation-induced cancer risk at this time 
point denotes a potential mechanism where the self-
elimination pathway is chosen over the DNA damage repair 
pathway [85, 86]. Such self-elimination is now known to 
occur by the p53-dependent apoptosis pathway [87-89]. On 
the other hand, exposure to the low-dose IR during later de-
velopmental stages in rodent models [86, 90] and human 
fetus [91-94] develop chromosomal aberrations or mutations 
leading to cancer. It is important to note that most assays 
testing the effects of IR on zebrafish embryos are conducted 
just few days after postfertilization and therefore fails to ac-
curately measure long-term consequences. With increased 
follow-up time, radiation may lead to alterations of behavior 
or responsiveness to the environment that can induce not an 
immediate death but a gradual lethal failure to thrive such as 
with impaired feeding capability [74, 76, 79, 80]. If ad-
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induce DNA repair to reverse radiation damages. Given the 
harmful and sometimes lethal long-term effects of IR, how-
ever, it remains uncertain that damage repair is a preferred 
survival mechanism than self-elimination.  
C. DNA Repair Proteins: Ku80 and ATM  
  Embryogenesis is a particularly radiosensitive stage of 
the vertebrate life cycle since the rapid cell division renders 
cells more vulnerable to the mistakes made by the error-
prone DNA repair mechanisms. Of the many IR-induced 
DNA lesions in the nucleus, double-stranded breaks (DSBs) 
appear to be the most predominant mutagenic lesion [re-
viewed in [95]]. Upon DSB formation, irradiated cells enter 
the DNA damage-dependent cell cycle arrest in an attempt to 
reestablish chromosome integrity by fixing the lesion [96-
99]. The DSB repair may occur either by nonhomologous 
end joining (NHEJ) or by homologous recombination [re-
viewed in [100, 101]]. If the repair is not properly carried 
out, a permanent cell cycle arrest, death, or oncogenesis may 
result [102-105]. Depending on the extent of DNA damage, 
however, a cell may resort to self-elimination by apoptosis 
instead [reviewed in [106]]. To date, the radioprotective 
function of only a few DNA repair proteins including the Ku 
proteins (Ku80 and Ku70) and ATM have been examined in 
irradiated zebrafish embryos. 
i. Ku80  
  The Ku protein, composed of Ku70 and Ku80 subunits, 
facilitates the initial DNA recognition step of NHEJ and is 
well studied in mammalian systems [107]. Several studies 
have cloned the zebrafish orthologue of human Ku80 in-
volved in NHEF pathway of DSB repair [108-110] and con-
firmed its role in the radiation-triggered DNA damage re-
sponse in zebrafish [73]. The Ku protein repair pathway re-
quires the presence of other proteins other than Ku70 and 
Ku80: LIG4 and XRCC4 encoding two subunits of a DNA 
ligase and PRKDC encoding the DNA-dependent protein 
kinases catalytic subunit. Knocking out any of these compo-
nents in mice results in severe radiosensitivity [reviewed in 
[100, 111]]. 
  Bladen and colleagues demonstrated that the expression 
of Ku80 in irradiated zebrafish embryos contribute to ra-
dioresistance by promoting damage repair rather than apop-
tosis. The zygotic transcription of Ku80 mRNA, encoded by 
the XRCC5 gene, is followed by its accumulation in specific 
tissue domains primarily consisting of rapidly proliferating 
cells, including organ-specific progenitor cells. Such tissue 
populations include the proliferative zones of the retina and 
central nervous system, specifically the retinal ganglion cells 
in the developing retina and the ventricular surface of the 
brain [112]. Moreover, the zygotic expression of Ku80 
mRNA significantly increased during gastrulation (6 hpf). 
The Ku80 function does not appear to be essential during 
embryonic development in the absence of genotypic stress, 
for zebrafish embryos with reduced Ku80 activity develop 
normally. However, when the Bladen group suppressed the 
Ku80 expression using antisense morpholino oligonucleo-
tides and subjected zebrafish embryos to low dose irradiation 
(50 cGy) during gastrulation, apoptosis was markedly 
upregulated throughout the developing CNS. The apoptosis 
exhibited was shown to be p53-dependent, indicating its ac-
tivation to be downstream of unrepaired DNA damage. The 
presence of DSB repair genes during early zebrafish devel-
oping therefore seems to play a critical role in shaping the 
balance between cell survival and apoptosis upon radiation 
stress.  
  Interesting to note is the radiation dose- and time-
dependency of apoptosis initiation after radiation treatment. 
Bladen et al. revealed the existence of a threshold radiation 
dose below which cell death does not occur. Zebrafish em-
bryos exhibited the absence of ectopic apoptotic cell death at 
15 cGy as compared to the substantial amount at only a 3-
fold higher radiation dose. This result has limitations, how-
ever, in choosing the endpoint for TUNEL analysis to be 24 
hpf after which the onset of embryonic pigmentation ob-
scured the signal. In addition, the ability to undergo apopto-
sis has been shown to take place at ~7 hpf in zebrafish em-
bryos [84]. Other studies have shown that IR-induced apop-
tosis initiation begins at later developmental time points such 
as the gastrulation stage [113-115]. Recently, Ku70 
(XRCC6) was shown to play a similar radioprotective role as 
Ku80 [116] and possesses the unique function of inhibiting 
the Bax-mediated apoptosis [117-119]. Further examining 
the ways in which Ku70 interact with the apoptosis and re-
pair pathway components may reveal the mechanism used to 
selectively choose either repair or self-elimination after irra-
diation.  
ii. ATM 
  The ataxia-telangiectasia mutated (ATM) encodes a nu-
clear serine/threonine kinase [120, 121] which takes on a key 
role in early response to DNA damage incurred by irradia-
tion [122-124]. Radiation activates ATM by triggering the 
dissociation of the inactive, dimeric ATM complex and the 
autophosphorylation of Ser
1981. The stimulated ATM then 
localizes to ionizing radiation-induced foci (IRIF) to catalyze 
the phosphorylation of many effector proteins regulating 
DNA repair, cell cycle arrest, apoptosis, and transcription 
[96, 105]. The ATM substrates include the tumor suppressor 
p53, NBS1, H2AX, breast cancer susceptibility gene 1 
(BRCA1), 53BP1,
  checkpoint kinase 2, 53BP1, Smc1, 
FANC2, H2AX, and Pin2/TRF1 [96, 122, 123, 125-131]. 
Mutation of the ATM gene causes ataxia-telangiectasia (A-
T), a rare autosomal recessive disorder (affecting approxi-
mately 1 of 40,000 to 1 of 100,000) characterized by neu-
rodegeneration, immunodeficiency, growth retardation, can-
cer predisposition and premature aging, as well as hypersen-
sitivity to ionizing radiation [132, 133].  
  Various animal models have been utilized to study the 
radioprotective effects of ATM especially in the CNS. Sev-
eral laboratories have generated ATM-knockout mice con-
taining specific germline inactivation of the ATM gene [134, 
135]. These mice display similar phenotypes as that of A-T 
patients even at cellular levels [136]. Common to all verte-
brate models is the absolute requirement of ATM in the 
normal CNS development and in the protection of develop-
ing CNS against radiation damages. During gastrulation and 
early neurulation, the ATM expression is particularly ele-
vated in the nervous system [120, 137]. ATM expression 
primarily in the CNS has been noted in Xenopus embryo 
[138] as well as in adult mouse and humans [139, 140]. Pre-
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ing neural cells with DNA damage [139, 141-143] through 
the apoptotic pathway [135]. 
  Zebrafish ATM (zATM) and human ATM (hATM) share 
a high level of homology as revealed through the PCR-based 
sequence analysis. Notably, the putative FAT phosphoinosi-
tide 3-kinase (PI3K)-like and FATC domains common to 
both zATM and hATM function in regulating the ATM 
kinase activity [144] and represent the most highly con-
served regions with 64-94% amino acid homology. Mean-
while, approximately 50% amino acid homology is exhibited 
outside these domains. In addition, dominant-negative muta-
tion sites of hATM as well as a number of identified muta-
tion sites in A-T patients are conserved in zATM [145-148]. 
Studying the effects of ATM expression during zebrafish 
development thus has important clinical implications in hu-
mans. 
  In the study by Imamura et al., the zATM knockout ze-
brafish model exhibited a heightened radiosensitivity upon 
irradiation. By in situ hybridization, it was shown that the 
ubiquitous zATM mRNA dramatically increased at the 18-
somite stage, then localized specifically in the eye, brain, and 
tail by 24 hpf and at later stages [149, 150]. Interestingly, the 
zATM mRNA present since 0.75 hpf (two-cell stage) were 
lost by 10 hpf (one-somite stage) but redetected at 19 hpf 
(20-somite stage). To examine the radioprotective effects of 
zATM, the group blocked the PI3K-like domain of zATM 
via  splice-blocking antisense-morpholino oligonucleotides 
and subjected the zATM-deficient embryos to 8 Gy of radia-
tion at 6 hpf. MO-based knockdown was highly penetrant in 
the first two days during which critical processes of somito-
genesis and organogenesis that can heighten the sensitivity to 
ionizing radiation occur. The resultant phenotypes of irradi-
ated embryos included the absence of pigmentation, lack of 
yolk extension, and extreme ventral body curvature. Treating 
the embryos with greater concentrations of zATM MO sig-
nificantly increased the mortality rate at 48 hpf and led to 
complete lethality by 72 hpf when combined with ionizing 
radiation. Under 8 Gy IR, 96.2% of the embryos injected 
with zATM MO exhibited the abnormal phenotype whereas 
only 3.5% of those uninjected was affected by radiation. 
Consistent with the previous finding that featured enhanced 
radiosensitivity in AMT-deficient mice embryos [151], this 
study suggests zATM to be a guardian of genotoxic stress.  
D. Radioprotection via Hematopoietic Cell Transplanta-
tion (HCT) 
  Pioneering studies by several laboratories have traced the 
fates of the BMT cells and showed that donor bone marrow 
contains rare cells generating clonal, macroscopic spleen 
colonies [152, 153], a fraction of which regenerated spleen 
colonies [154], and repopulating multilineage hematopoiesis 
[155]. These experiments gave rise to the concept of the he-
matopoietic stem cell (HSC). The HSC transplantation has 
not only been used to test transformation in mouse cancer 
cell models but also to test the radioprotective properties of 
hematopoietic stem cells in irradiated zebrafish. Minimum 
lethal dose (MLD) has been shown to ablate cells of blood-
forming tissues and nearly all leukocyte subsets residing in 
the kidney within a week before death. The seminal murine 
studies further demonstrated the rescue of acute irradiation 
syndrome by bone marrow transplantation (BMT) [156, 
157]. Moreover, recent mouse studies indicate that the trans-
plantation of megakaryocyte or erythrocyte progenitor cells 
is sufficient for radioprotection following the MLD [158].  
  With these evidences in hand, Traver and colleagues hy-
pothesized that irradiation-induced mortality is due to hema-
topoietic failure and attempted to rescue irradiated zebrafish 
embryos by transplanting hematopoietic cells. A minimum 
lethal dose (MLD) of 40 Gy led to the specific ablation of 
hematolymphoid cells and death by 14 days after irradiation. 
Having found previously that the adult zebrafish kidney con-
tains long-term HSCs and its downstream progenitor cells, 
[159], the group transplanted whole kidney marrow (WKM) 
cells into the lethally irradiated zebrafish 2 days after irradia-
tion. If the hematopoietic failure is the only lethal conse-
quence of a 40-Gy dose, then HCT should arrest the plum-
meting survival rate of the irradiated zebrafish. Indeed, 
WKM transplantation into these zebrafish resulted in a 70% 
survival rate over 30 days compared to the controls which all 
died by 14 days after irradiation. The transplanted WKM 
cells carried transgenes yielding red fluorescent erythrocytes 
and green fluorescent leukocytes, and this allowed the visu-
alization of donor-derived cells repopulating the recipient 
hematolymphoid tissues. Previous experiments replicate the 
results of current study in showing that HCT sufficiently 
radioprotects normal tissues from otherwise lethal doses of 
radiation [156, 160-165]. It was once thought that humoral 
factors produced from the transplanted hematopoietic tissues 
act as radioprotective elements [164].  
  Traver and colleagues also points out the role of tempera-
ture in affecting the degree of radioprotection. Nearly 40 Gy 
of IR was required for the MLD in zebrafish, contrasting 
with only 9 to 10 Gy needed for the same effect in mammals. 
It was previously shown that cold-blooded animals (i.e. ze-
brafish) are more radioresistant than warm-blooded animals 
[166]. Additional data further confirm the strong negative 
correlation between temperature and radioresistance. In 
mice, for example, the temporary reduction in ambient tem-
perature to 0 - 0.5°C allows the radiation dose required for 
half of the animals to die over 30 days (LD50/30) to increase 
from 6.2 Gy to 18 Gy [167]. Histologic studies in both 
mammals and teleosts demonstrate that radiation damages 
are less severe at lower temperatures at the cellular level 
[168]. Additionally, the life span of erythrocytes has also 
been shown to increase upon temperature reduction [169]. 
Given that blood cell repopulation is crucial for survival fol-
lowing irradiation, the observed correlation between radiore-
sistance and temperature may be due to both to metabolic 
and life span alteration of irradiated erythrocytes until a 
complete recovery of host hematopoiesis. 
III. RADIOSENSITIZERS: AG1478 AND FLAVOPI- 
RIDOL 
A. AG1478 
  Zebrafish as a model system has also been of great use in 
screening for potential radiosensitizers. McAleer and col-
leagues documented both the effects of radioprotector ami-
fostine and radiosensitizer AG1478, a tyrosine kinase inhibi-
tor, introducing the concept of using zebrafish not only to 
screen antineoplastic agents [5], but also to test radiation Zebrafish as a Model System to Screen Radiation Modifiers  Current Genomics, 2007, Vol. 8, No. 6    365 
modifiers [72]. AG1478 is an epidermal growth factor recep-
tor (EGFR) tyrosine kinase inhibitor shown to radiosensitize 
human cells in vitro and in preclinical xenograft experiments 
[170]. In comparison to the control, zebrafish embryos pre-
treated with 2.5-5 μM AG1478 and +4 Gy X-rays at 4 hpf 
displayed approximately a 20% reduction in the survival rate 
and a significantly enhanced teratogenicity as early as 72 
hpf. Although the mechanism behind the radiosensitizing 
action of AG147 was not mentioned, the experiment strongly 
suggests zebrafish as a model system to be used in the test-
ing of not only radioprotectors but also radiosensitizers.  
B. Flavopiridol 
  McAleer and colleagues further tested the radiosensitiz-
ing effects of a cell cycle inhibitor termed flavopiridol [171]. 
Flavopiridol is a small-molecule semisynthetic flavonoid that 
functions to inhibit cyclin dependent kinases [172] and affect 
various signal transduction cascades [173, 174]. The abroga-
tion of G1/S cell cycle check point following the inhibition 
of cyclin D1 blocks the progression of cells into S phase, the 
stage which supposedly exhibits radioresistance [175]. 
Hence, the cyclin D1 inhibition via flavopiridol should ra-
diosensitize cells to the harmful effects of IR as compared to 
controls. The in vivo radiosensitizing effect of the flavonoid 
has been exhibited in a murine model system xenografted 
with human [176] and syngeneic mouse tumors [177, 178]. 
Additionally, flavopiridol has been reported to induce radio-
sensitization in various human cancers including esophageal 
[179], prostate [180], ovarian [178], colon, gastric [181], and 
leukemic [182] carcinomas. The clinical trials [183] showed 
discouraging results, however, due to the significant toxicity 
when administered as monotherapy [184] and when co-
administered with chemotherapeutic agents [185, 186].  
  Flavopiridol has been shown to radiosensitize zebrafish 
to the same extent as with antisense oligomers to cyclin D1. 
McAleer et al. treated 1- to 4-cell stage zebrafish embryos 
with 500 nM flavopiridol, previously concluded as the bio-
logically active concentration [183], and with 0.5 pmol an-
tisense hydroxylprolyl-phosphono peptide nucleic acid 
(HypNA-pPNA) oligomers to test the radiosensitizing effects 
of reducing cyclin D1 expression. Both treatments induced 
almost a twofold increase in mortality after exposure to 40 
Gy by 96 hpf and more severe morphologic changes as com-
pared to the control. Most noticeably, exposure to 40 Gy 
resulted in 100% of control embryos with defective midline 
development labeled as the cup or “curly up” phenotype, 
whereas only 20 Gy was necessary to induce the same result 
in flavopiridol or oligomer-treated embryos. Whereas none 
of the treated embryos survived under the maximal radiation 
dose of 40 Gy, approximately half of the irradiated control 
embryos remained viable by 120 hpf (p = 0.026). Evident 
from these results is that the inhibition cyclin D1 appears 
sufficient enough to account for the radiosensitization in 
flavopiridol and (HypNA-pPNA) oligomer-treated zebrafish 
embryos. 
IV. FUTURE DIRECTIONS 
  Zebrafish has indeed proven to be an ideal model organ-
ism whose radiation shielding mechanisms may aid in the 
identification of radioprotectors and radiosensitizers pivotal 
to radiotherapy. Zebrafish studies on radioprotectors such as 
amifostine cast a new hope in resolving the dilemma of col-
lateral tumor protection in the context of radioprotective 
agents. Studies on the effects of Flavopiridol and AG1478 in 
zebrafish also foreshadow a potential future scenario of se-
lectively radiosensitizing tumor cells, although much needs 
to be done before it comes to fruition. When combined ad-
vanced radiotherapies such as the Intensity-Modulated Ra-
diation Therapy (IMRT), such chemical radiation modifiers 
will help enhance the selective targeting of tumor tissues in 
the future. Given the high homology of repair genes and the 
similar mutagenic phenotypes between zebrafish and mam-
mals under genotoxic stress, the radioprotection mechanisms 
in zebrafish thus has far-reaching clinical implications.  
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